Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lactiplantibacillus plantarum 815
- Development stage
- Unknown
- Lead developer
- Verb Biotics
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
*Lactiplantibacillus plantarum* 815 (formerly *Lactobacillus plantarum* 815) is a probiotic bacterial strain developed as a live biotherapeutic product (LBP). It is primarily being investigated by Medytox for the treatment of obesity and metabolic syndrome. The strain is thought to exert its effects by modulating the gut microbiome, reducing systemic inflammation, and influencing lipid metabolism pathways. Clinical studies have focused on its ability to reduce body fat and improve metabolic parameters in overweight and obese individuals. The strain was reclassified into the genus *Lactiplantibacillus* following a major taxonomic revision of the *Lactobacillus* genus in 2020.
- Brand names
- GABA Probiotic LP815
- Other names
- Lactobacillus plantarum 815L. plantarum 815
Beyond the preview
Go deeper on Lactiplantibacillus plantarum 815.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lactiplantibacillus plantarum 815.